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The inaugural ISSCR Outstanding Young Investigator Award was awarded to Konrad Hochedlinger in
recognition of exceptional achievements in the early part of his independent stem cell research career.The International Society for Stem Cell Research (ISSCR) has
selected Konrad Hochedlinger as the recipient of its 2009
Outstanding Young Investigator Award. The award, supported
by the University of Pittsburgh, was instigated this year to high-
light the achievements of an exceptional early-career scientist. In
the words of Fred H. Gage, Professor and Vi and John Adler
Chair for Research on Age-Related Neurodegenerative Diseases
at the Salk Institute and Chair of the ISSCR Awards Committee,
‘‘The ISSCR developed the Young Investigator Award to recog-
nize and encourage the new generations of scientists committed
to stem cell biology. The remarkable list of nominees this year
attests to the fact that the field is strong and vibrant. Konrad is
a terrific example of the quality of young scientist attracted to
the expanding opportunities in this field.’’ We could not agree
more on all points.
Konrad Hochedlinger is an Assistant Professor in Harvard’s
Department of Stem Cell and Regenerative Biology and a Prin-
cipal Faculty member of the Harvard Stem Cell Institute. He is
a Principal Investigator in the Massachusetts General Hospital
(MGH) Center for Regenerative Medicine where he maintains
his laboratory and in the MGH Cancer Center. Konrad
completed his graduate training with one of us (R.J.) at the
Whitehead Institute for Biomedical Research, although his
Doctoral degree was awarded by the Research Institute of
Molecular Pathology, University of Vienna in the spring of
2003. Konrad, soon after joining the laboratory, demonstrated
his remarkable scientific ability in an exceptionally elegant
experiment. After the publication of Dolly (Wilmut et al., 1997),
one of the major unresolved questions of the mammalian
cloning field had been whether clones
could be derived from the nucleus of
a terminally differentiated cell as
assumed in the original experiment rather
than from nuclei of somatic stem cells
present in the heterogeneous donor cell
population. Konrad’s initial PhD work
resolved this question leading to a truly
landmark publication; he used nuclear
transfer (NT) to demonstrate that termi-
nally differentiated murine B and T
lymphocytes could be cloned via a clever
two-step protocol to generate mono-
clonal mice (Hochedlinger and Jaenisch,
2002). This work was accomplished
almost simultaneously with another
project that demonstrated the first proof
of principle that NT in combination with
gene and cell therapy could be used to
improve the disease phenotype in a mouse model of congenital
immunodeficiency (Rideout et al., 2002). This was followed by
another ingenious use of NT to demonstrate that even malignant
melanoma cells were capable of being reprogrammed to devel-
opmental pluripotency and that chimeric mice generated with
the resulting NT-ESCs remained cancer prone (Hochedlinger
et al., 2004).
After a brief postdoctoral experience at the Whitehead,
Konrad started his own laboratory at Harvard and MGH in 2006.
In the few short years since then, the pace of his research in
cellular reprogramming has only accelerated. Konrad’s labora-
tory has made major contributions to the reprogramming litera-
ture, building upon the original observations of Shinya Yama-
naka to generate induced pluripotent stem cells (iPSCs) that
showed in vitro virally delivered, gene-based reprogramming of
somatic cells (Takahashi and Yamanaka, 2006). Konrad’s labo-
ratory demonstrated improved performance of fully reprog-
rammed human iPSCs and creatively exploited conditional
transgene expression cassettes to define the temporal events
of reprogramming; his group has investigated the epigenetic
modifications that accompany reprogramming and was the first
to demonstrate the generation of transgene-free iPSCs via
adenoviral gene transfer (Maherali et al., 2008; Maherali et al.,
2007; Stadtfeld et al., 2008a; Stadtfeld et al., 2008b). Konrad’s
laboratory contributed to the production of the first large repos-
itory of patient-specific iPSCs (Park et al., 2008).
Finally, to all of us who have worked closely with Konrad, we
feel privileged to have such a warm and generous colleague in
our midst. We anticipate more spectacular scientific contribu-
tions in the years ahead, and offer our
most heartfelt congratulations on his
recognition with the 2009 ISSCR
Outstanding Young Investigator Award.
It is most deserved.
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